nach oben

Erschienen in:

Open Access 01.12.2022 | COVID-19 | Research

SARS-CoV-2 omicron variant clearance delayed in breakthrough cases with elevated fasting blood glucose

verfasst von: Xiujun Zhang, Guocan Si, Huifen Lu, Wei Zhang, Shuqin Zheng, Zeyu Huang, Longgen Liu, Yuan Xue, Guojun Zheng

Erschienen in: Virology Journal | Ausgabe 1/2022

Abstract

Background

Omicron variant (B.1.1.529) is a dominant variant worldwide. However, the risk factors for Omicron variant clearance are yet unknown. The present study aimed to investigate the risk factors for early viral clearance of Omicron variant in patients with a history of inactivated vaccine injection.

Methods

Demographic, clinical, and epidemiological data from 187 patients were collected retrospectively during the Omicron variant wave.

Results

73/187 and 114/187 patients were administered two and three doses of vaccine, respectively. The median duration of SARS-CoV-2 RNA positivity was 9 days, and the difference between patients with two and three vaccine injections was insignificant (P = 0.722). Fever was the most common symptom (125/187), and most patients (98.4%) had a fever for < 7 days. The RNA was undetectable in 65/187 patients on day 7. Univariable logistic analysis showed that baseline glucose, uric acid, lymphocytes count, platelet count, and CD4⁺ T lymphocyte count were associated with SARS-CoV-2 RNA-positivity on day 7. Multivariable analysis showed that glucose ≥ 6.1 mmol/L and CD4⁺T lymphocytes count were independent risk factors for RNA positivity on day 7. 163/187 patients had an undetectable RNA test on day 14, and uric acid was the only independent risk factor for RNA positivity. Moreover, baseline glucose was negatively correlated with uric acid and CD4⁺ and CD8⁺ T cell count, while uric acid was positively correlated with CD4⁺ and CD8⁺ T cell count.

Conclusions

Omicron variant clearance was delayed in breakthrough cases with elevated fasting blood glucose, irrespective of the doses of inactivated vaccine.

Xiu-Jun Zhang and Guo-Can Si contributed equally to this work

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2

RBD

Receptor-binding domain

ACE2

Angiotensin-converting enzyme 2

mAbs

Monoclonal antibodies

NTD

Amino-terminal domain

COVID-19

Coronavirus disease 2019

RT-PCR

Reverse transcriptase-polymerase chain reaction

Cycle threshold

IQR

Interquartile range

Computed tomography

Odds ratio

Confidence interval

Background

In the past 2 years, approximately 527 million patients have been infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and 6.3 million were deceased globally. Omicron variant (B.1.1.529), first reported in November 2021, has become the dominant variant worldwide [1, 2]. Although its virulence is weak, SARS-CoV-2 is more transmissible and infectious than other variants of concern [1, 3].

The spike receptor-binding domain (RBD) in the Omicron variant has enhanced binding properties with the human angiotensin-converting enzyme 2 (ACE2) receptor, which facilitates cell permeability [4]. Since RBD is the primary target of neutralizing antibodies upon vaccination or infection, whether mutations in RBD can affect the neutralizing activity of monoclonal antibodies (mAbs), leading to immune escape, is a significant concern [5, 6]. Moreover, mutations in the amino-terminal domain (NTD) also reduce the protectivity of the vaccine. Data from a multicenter retrospective study from Singapore showed that viral load was similar between vaccinated and unvaccinated patients at diagnosis. The mRNA vaccine caused a rapid decline in the Delta variant’s viral load of the Delta variant [7]. Another study showed that the viral load was lower in patients infected within 6 months of vaccination compared to the unvaccinated individuals, while no significant difference was detected in the viral load between patients vaccinated > 6 months before infection and unvaccinated individuals [8]. However, data about convalescent plasma or vaccines against the Omicron variant are disappointing [9‐12]. Sera from convalescent patients infected by the Delta variant or vaccinated individuals showed low or no neutralizing activity against the Omicron variant [9, 11]. Although antibodies generated by a booster vaccine show a lower response against the Omicron variant than Delta, accumulating evidence warranted the administration of a booster vaccine dose [11, 13].

Based on previous studies, blood glucose predicted the mortality of coronavirus disease 2019 (COVID-19), even in patients without a history of diabetes [14‐16]. High fasting plasma glucose level (≥ 6.1 mmol/L) at admission is an independent predictor for prolonged SARS-CoV-2 shedding [17]. Individuals with hyperglycemia had lower spike IgG titer than those with normoglycemia after two doses of the BNT162b2 vaccine, indicating that hyperglycemia is associated with a poor humoral immune response [18]. In young adults with type 1 diabetes, the elevated glucose level is positively associated with persistent symptoms [19]. The in vitro experiment confirmed that increased glucose concentration decreases the viability of A549 cells and induces ACE2 overexpression [20]. In addition, viral loads are high, and respiratory tissue damage is severe in the diabetic mice model [21].

To date, the risk factors for Omicron variant clearance are yet unknown. Herein, we investigated the risk factors for 7- and 14-day viral clearance post-infection of Omicron variant in patients with a history of inactivated vaccine injection.

Methods

Patients

A total of 239 patients with COVID-19 were admitted to the Third People’s Hospital of Changzhou between March 13, 2022 and May 10, 2022. All the patients were diagnosed according to the Chinese guidelines for the diagnosis and treatment of COVID-19 [22]. COVID-19 was diagnosed based on the epidemiological history and the positive RNA test in the throat swabs. Biochemical examination and a computed tomography (CT) scan were given routinely at admission. According to the guidelines for the prevention and treatment of diabetes, the disease was diagnosed based on the history of the patient, glycated hemoglobin (HbA1c), and repeated fasting glucose tests [23]. Demographic, clinical, and epidemiological data were retrospectively collected from electronic medical records and a laboratory information management system.

Reverse transcriptase-polymerase chain reaction (RT-PCR) assay

COVID-19 was confirmed based on the RT-PCR assay performed by the Laboratory of the Third People’s Hospital of Changzhou using a commercial kit (Jiangsu Bioperfectus Technologies Co., Taizhou, China). According to the manufacturer’s instructions, cycle threshold (Ct) values of ORF1ab and N genes < 35 indicated a positive RNA test. Duplicate tests were performed at 24 h if the result was negative (Ct ≥ 35).

Statistical analysis

All analyses were performed using SPSS 25.0 software (Armonk, NY, USA). Data were expressed as median (interquartile range, IQR) or frequencies and compared using the Kruskal–Wallis test or chi-square test. Correlation analysis was performed using Spearman’s correlation test. Logistic regression analysis was conducted to identify the independent risk factors for viral clearance. A two-sided P-value < 0.05 was considered statistically significant.

Results

Baseline characteristics of patients with COVID-19

Among the 239 patients with COVID-19, 52 were excluded because of the undefined history of the vaccine. Data from 187 patients were analyzed, including 73 patients who had two doses of vaccine injection and 114 patients who received three doses. The duration from the first, second, and third vaccine injections to infection was defined as T1, T2, and T3, respectively. Only 5 patients had a T2 < 6 months, and none of the patients had a T3 < 1 month.

For comorbidity, 3 patients had chronic hepatitis B, 8 had diabetes, 17 had hypertension, 1 had pulmonary tuberculosis, and 1 had chronic kidney disease. None of the patients was administered glucocorticoid or immunosuppressor at admission or during hospitalization.

A total of 43 patients had elevated fasting blood glucose (≥ 6.1 mmol/L) at admission, among whom 7 patients had a diabetes history, and 1 patient was diagnosed with diabetes during hospitalization. Among the 35 patients who were not diagnosed with diabetes, the fasting blood glucose in 17 patients decreased to a normal level in a week without any hypoglycemic treatment, and 18 patients with slightly elevated glucose (≥ 6.1 mmol/L and < 7.5 mmol/L) did not undergo a repeat test. In addition, only 9 patients had a glucose ≥ 7.9 mmol/L at admission, and 4 patients had a normal glucose level in a week and were excluded from diabetes.

Fever was the most common symptom (125/187, 66.8%), and most patients (123/125, 98.4%) had a fever duration of < 7 days. Other symptoms included cough (30/187, 16.0%), pharyngalgia (22/187, 11.8%), muscular soreness (9/187, 4.8%), headache (9/187, 3.2%), and diarrhea (6/187, 3.2%). According to CT scans, 13 individuals were diagnosed with unilateral pneumonia and 6 with bilateral pneumonia, while none developed severe pneumonia or ARDS. The median duration of SARS-CoV-2 RNA-positivity was 9 days, and the difference between patients with two and three doses of vaccine injection was insignificant (Z = 0.356, P = 0.722).

Characteristics of patients with and without SARS-CoV-2 clearance on day 7

As shown in Table 1, 65 (34.8%) patients had an undetectable RNA test on day 7. No significant difference was detected in age, diabetes, T1, T2, and duration of fever between patients with and without SARS-CoV-2 clearance. Patients with viral clearance on day 7 had a lower glucose level than those with a positive RNA test (Z = 3.943, P < 0.01). In addition, neutrophils were higher, while the lymphocyte and platelet counts were lower in patients with a positive RNA test than those with a negative RNA test (Z = 2.160, 2.014, and 2.114, respectively; P < 0.05). Moreover, CD4⁺ T lymphocytes were higher in patients with viral clearance on day 7 (Z = 2.647, P < 0.01).

Table 1

Characteristics of patients with and without SARS-CoV-2 on day 7

Variables	Positive (n = 122)	Negative (n = 65)	Z or χ²	P value
Age, years	47.5(34–52)	43(33–50.5)	1.495	0.14
Male, n(%)	90(73.8)	53(81.5)	1.422	0.23
Diabetes, n(%)	6(4.9)	2(3.1)	0.351	0.72
T1,days	305.5(263.8–348.5)	315.0(265.5–348.0)	0.065	0.95
T2,days	275.5(233.5–310.3)	274.0(234.5–315.0)	0.031	0.98
Duration of fever, days	2.0(0–3.0)	1.0(0–2.0)	1.277	0.20
Laboratory findings
ALT, U/L	20.2(15.0–33.2)	21.7(14.8–41.5)	0.555	0.58
AST, U/L	19.5(16.0–25.0)	20.0(16.5–25.5)	0.526	0.60
Glucose, mmol/L	5.4(4.8–6.3)	4.8(4.5–5.5)	3.943	< 0.01
Creatinine, µmol/L	69.3(58.1–76.9)	69.5(58.9–79.6)	0.546	0.59
Uric acid, µmol/L	304.6(259.5–363.9)	329.8(273.3–395.3)	1.806	0.07
CRP, mg/L	4.0(2.0–11.1)	4.7(1.9–9.3)	0.338	0.74
Neutrophils, E + 09/L	4.2(3.2–5.3)	3.6(2.4–5.0)	2.160	0.03
Lymphocytes, E + 09/L	1.1(0.7–1.4)	1.2(0.9–1.6)	2.014	0.04
Platelets, E + 09/L	202.0 (174.8–234.3)	224.0(188.5–257.5)	2.114	0.04
CD4⁺T	424.0(275.8–647.8)	550.0(412.0–705.5)	2.647	< 0.01
CD8⁺T	310.5(203.8–483.0)	359.0(260.5–494.0)	1.550	0.12
B cells count	123.0(79.0–233.0)	158.0(99.0–258.0)	1.963	0.05
CT findings
Unilateral pneumonia, n(%)	10(8.20)	3(4.62)	0.841	0.55
Bilateral pneumonia, n(%)	4(3.28)	2(3.08)	0.006	0.99

Data were expressed as median (IQR) for continuous variables and n (%) for categorical values, and were compared using Kruskal–Wallis test or Chi-square test. T1, duration from the first infection of vaccine to diagnosis; T2, duration from the second infection of vaccine to diagnosis; ALT, alanine aminotransferase; AST, aspartate transaminase; CRP, C-reaction protein; CT, computer tomography

Risk factors for SARS-CoV-2 RNA positivity on day 7

As shown in Table 2, the univariable logistic analysis showed that baseline glucose, uric acid, lymphocyte count, platelet count, and CD4⁺T lymphocyte count are associated with SARS-CoV-2 RNA positivity on day 7. Then, multivariable analysis showed that baseline glucose and CD4⁺T lymphocytes count were independent risk factors for SARS-CoV-2 RNA positivity on day 7 (odds ratio (OR) = 0.631 and 1.001, 95% confidence interval (CI): 0.456–0.874 and 1.000–1.002, P < 0.01 and P = 0.02, respectively).

Table 2

Risk factors for SARS-CoV2 clearance on day 7

Baseline variables	Univariate			Multivariate
Baseline variables	Odds ratio	95%CI	P	Odds ratio	95%CI	P
Age (years)	0.979	0.955–1.005	0.11
Sex	0.637	0.302–1.342	0.24
T1	0.999	0.994–1.005	0.87
T2	1.000	0.995–1.006	0.91
ALT	1.004	0.991–1.017	0.53
Glucose	0.607	0.433–0.851	< 0.01	0.631	0.456–0.874	< 0.01
Creatinine	1.006	0.987–1.025	0.55
Uric acid	1.003	1.000–1.007	0.07
Lymphocytes	1.668	1.026–2.712	0.04
Platelets	1.006	1.000–1.011	0.04
CD4 + T cells	1.001	1.000–1.002	< 0.01	1.001	1.000–1.002	0.02
CD8 + T cells	1.001	0.999–1.002	0.28
B cells	1.002	1.000–1.004	0.11

CI, 95% confidence interval; T1, duration from the first infection of vaccine to diagnosis; T2, duration from the second infection of vaccine to diagnosis; ALT, alanine aminotransferase

More patients had a glucose level ≥ 6.1 mmol/L at admission in the RNA-positive group (35/122, 28.7%) compared to those in the RNA-negative group (8/65, 12.3%) (χ² = 6.426, P = 0.01). Then, the multivariable analysis used glucose ≥ 6.1 mmol/L as a categorical value, and the data showed that glucose ≥ 6.1 mmol/L and CD4⁺ T lymphocytes count were independent risk factors for SARS-CoV-2 RNA-positivity on day 7 (OR = 0.351 and 1.001, 95% CI: 0.150–0.825 and 1.000–1.002, P = 0.02 and P = 0.01, respectively).

Characteristics of patients with and without SARS-CoV-2 clearance on day 14

As shown in Table 3, most patients had an undetectable RNA test on day 14 (163/187, 87.2%). Patients with viral clearance at day 14 had higher uric acid levels and lymphocyte counts than those with a positive RNA test (Z = 2.997 and 2.084, P < 0.01 and = 0.04, respectively). The CD4⁺ and CD8⁺ T cell count was high in patients with viral clearance (Z = 2.382 and 2.094, both P < 0.05).

Table 3

Characteristics of patients with and without SARS-CoV-2 on day 14

Variables	Positive (n = 24)	Negative (n = 163)	Z or χ²	P value
Age, years	46.5(40.0–56.5)	46.0(34.0–51.0)	1.132	0.26
Male, n (%)	17(70.8)	126(77.3)	0.486	0.49
Diabetes, n (%)	2(8.3)	6(3.7)	1.106	0.27
T1, days	290.0(258.5–321.3)	315.0(266.0–352.0)	1.737	0.08
T2, days	270.0(221.5–291.8)	275.0(234.0–317.0)	0.998	0.32
Duration of fever, days	2.0(0–4.0)	1.0(0–3.0)	0.537	0.59
Laboratory findings
ALT, U/L	19.6(13.0–26.2)	21.1(15.3–37.1)	1.636	0.10
AST, U/L	19.0(16.0–22.0)	20.0(16.0–25.0)	0.670	0.50
Glucose, mmol/L	5.4(4.8–6.7)	5.1(4.7–5.9)	1.526	0.13
Creatinine, µmol/L	75.8(55.9–82.7)	69.0(58.5–76.9)	1.539	0.12
Uric acid, µmol/L	269.3(224.2–316.8)	322.4(270.3–380.2)	2.997	< 0.01
CRP, mg/L	6.8(3.4–11.1)	3.9(1.8–9.6)	1.695	0.09
Neutrophils, E + 09/L	3.6(2.9–4.6)	4.1(3.0–5.3)	1.244	0.21
Lymphocytes, E + 09/L	0.8(0.6–1.3)	1.1(0.8–1.5)	2.084	0.04
Platelets, E + 09/L	193.5(161.3–222.5)	209.0(179.0–252.0)	1.810	0.07
CD4⁺T	387.5(238.0–503.0)	482.0(332.0–693.0)	2.382	0.02
CD8⁺T	291.0(162.5–384.0)	346.0(220.0–495.0)	2.094	0.04
B cells count	11.4(7.8–16.2)	11.8(7.9–16.2)	0.215	0.83
CT findings
Unilateral pneumonia, n(%)	6(25.0)	7(4.3)	13.865	< 0.01
Bilateral pneumonia, n(%)	1(4.2)	5(3.1)	0.081	0.57

Risk factors for SARS-CoV-2 RNA positivity on day 14

As shown in Table 4, the univariate logistic analysis showed that baseline uric acid, lymphocyte count, platelet count, and CD4⁺ and CD8⁺ T lymphocyte count were associated with SARS-CoV-2 RNA-positivity on day 14. Then, multivariate analysis showed that only baseline uric acid is the independent risk factor for SARS-CoV-2 RNA positivity on day 14 (OR = 1.008, 95% CI: 1.002–1.014, P = 0.01).

Table 4

Risk factors for SARS-CoV2 clearance on day 14

Baseline variables	Univariate			Multivariate
Baseline variables	Odds ratio	95%CI	P	Odds ratio	95%CI	P
Age (years)	0.973	0.938–1.009	0.14
Sex	0.713	0.275–1.850	0.49
T1	1.007	0.998–1.016	0.12
T2	1.004	0.997–1.012	0.27
ALT	1.015	0.990–1.042	0.24
Glucose	0.899	0.734–1.101	0.30
Creatinine	0.980	0.956–1.005	0.11
Uric acid	1.008	1.002–1.014	0.01	1.008	1.002–1.014	0.01
Lymphocytes	2.677	0.986–7.266	0.05
Platelet	1.009	1.000–1.018	0.05
CD4⁺T cells	1.002	1.000–1.004	0.04
CD8⁺T cells	1.003	1.000–1.006	0.03
B cells	1.003	0.999–1.007	0.20

CI, 95% confidence interval; T1, duration from the first infection of vaccine to diagnosis; T2, duration from the second infection of vaccine to diagnosis; ALT, alanine aminotransferase

Adjusted multivariable analysis was conducted when CD4⁺ and CD8⁺ T lymphocyte count was deleted, and data showed that uric acid is the only independent risk factor for SARS-CoV-2 RNA positivity on day 14.

Correlation between glucose, uric acid, CD4⁺T, and CD8⁺T cell count

As shown in Fig. 1, baseline glucose was negative with uric acid, lymphocyte count, CD4⁺ T cell count, and CD8⁺ T cell count (all P < 0.05), while uric acid was positively correlated with CD4⁺ T cell and CD8⁺ T cell count (both P < 0.05). In addition, there was a positive correlation between CD4⁺ T and CD8⁺ T cell count (r = 0.710, P < 0.01).

Discussion

In the present study, we investigated the risk factors for early clearance of Omicron variant in patients with a history of inactivated vaccine injection. On day 7 after admission, 34.8% of patients had an undetectable RNA test, and baseline glucose ≥ 6.1 mmol/L and CD4⁺ T lymphocyte count were independent risk factors for SARS-CoV-2 RNA positivity. On day 14 after admission, SARS-CoV-2 RNA became undetectable in 87.2% of patients, and uric acid was the only independent risk factor for RNA-positivity.

The knowledge of prolonged SARS-CoV-2 shedding during Omicron waves is limited, especially for patients receiving inactivated vaccine injections. For most mAbs, the neutralizing activity against the Omicron variant is limited [10, 11, 24]. Wang et al. reported that the seroconversion rate of neutralizing antibodies was just 3.3% for individuals who received two doses of inactivated vaccine, while the rate was 95% for those who received three doses of vaccine [25]. Nonetheless, the neutralizing antibody titer induced by three vaccine doses was 16.5-fold low for the Omicron variant [25]. In the present study, the duration of SARS-CoV-2 shedding was similar between patients who received two and three doses of the vaccine. Thus, it can be speculated that mutations in RBD affect the neutralizing activity of antibodies induced by the inactivated vaccine. Since most patients were vaccinated > 6 months before infection, the long interval from vaccination to infection may account for the non-optimal protection activity. These results suggest that effective vaccine strategies are warranted.

Several studies indicated that glucose at admission is an independent risk factor for the poor prognosis of COVID-19 during the Delta variant wave [15, 16, 20]. Moreover, high glucose at admission is an independent predictor for prolonged SARS-CoV-2 shedding, irrespective of a history of diabetes [17]. Similar results were obtained in the present study during the Omicron variant wave. Glucose-like metabolite deficiency may facilitate viral entry and replication, as described previously [21]. Another mechanism is that the production of neutralizing antibodies is reduced in diabetes [18, 26]. In addition, our results showed that CD4⁺ T cell count is low in patients without early viral clearance and is negatively related to glucose. Thus, glucose and cellular immunity regulation may be an appropriate strategy for managing COVID-19.

The present data showed that uric acid is the only independent predictor for SARS-CoV-2-positivity on day 14, negatively correlated with glucose, and positively correlated with CD4⁺ and CD8⁺ T cells. Interestingly, the patients with lower serum uric acid levels experienced severe symptoms than those with higher uric acid levels [27, 28]. SARS-CoV-2 induces low serum uric acid [28] level and causes hyperglycemia in a cat model [29]. The interactions between uric acid, glucose, impaired cellular or humoral immunity, and viral replication are yet to be elucidated. Although diabetes is detected in only a few cases in the present study, elevated fasting blood glucose was a common phenomenon at admission; however, the underlying mechanisms are yet unknown. Moreover, the effect of hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, on COVID-19 remains an interesting issue worth exploration [30].

The main limitation of the present study is that neutralizing antibodies at admission are not estimated. Regarding the Omicron variant spread, data from the present study highlighted the potential predictive value of metabolic factors, such as glucose and uric acid, in clinical practice. Typically, the benefits of the vaccine outweigh the potential risks [31, 32]; hence, vaccination during the pandemic of the Omicron variant should be administered without hesitation. Since outbreaks of COVID-19 occurred in different cities, a multicenter study with large sample size is warranted. Another limitation is that only 3 patients received HbA1c tests; otherwise, sufficient data could have been collected.

Conclusion

Omicron variant clearance was delayed in breakthrough cases with elevated fasting blood glucose, regardless of the inactivated vaccine doses.

Acknowledgements

Not applicable.

Declarations

This study was approved by the Ethics Committee of the Third People’s Hospital of Changzhou, and was performed in accordance with the 2013 Declaration of Helsinki.

Written consent was exempted for this retrospective study.

Competing interests

The authors declare no conflict of interest.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 omicron variant. N Engl J Med. 2022;386(7): e14. https://doi.org/10.1056/NEJMp2119682.CrossRefPubMed

Mohapatra RK, Tiwari R, Sarangi AK, et al. Omicron (B11529) variant of SARS-CoV-2: concerns, challenges, and recent updates. J Med Virol. 2022;94(6):2336–42. https://doi.org/10.1002/jmv.27633.CrossRefPubMedPubMedCentral

Guo Y, Han J, Zhang Y, et al. SARS-CoV-2 omicron variant: epidemiological features, biological characteristics, and clinical significance. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.877101.CrossRefPubMedPubMedCentral

Islam F, Dhawan M, Nafady MH, et al. Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: mutational impacts, concerns, and the possible solutions. Ann Med Surg (Lond). 2022. https://doi.org/10.1016/j.amsu.2022.103737.CrossRef

Rossler A, Knabl L, von Laer D, Kimpel J. Neutralization Profile after recovery from SARS-CoV-2 omicron infection. N Engl J Med. 2022;386(18):1764–6. https://doi.org/10.1056/NEJMc2201607.CrossRefPubMed

Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants. N Engl J Med. 2022;386(16):1579–80. https://doi.org/10.1056/NEJMc2201849.CrossRefPubMed

Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect. 2022;28(4):612 e611-612 e617. https://doi.org/10.1016/j.cmi.2021.11.010.CrossRef

Bramante CT, Proper JL, Boulware DR, et al. Vaccination against SARS-CoV-2 is associated with a lower viral load and likelihood of systemic symptoms. Open Forum Infect Dis. 2022;9(5):ofac066. https://doi.org/10.1093/ofid/ofac066.CrossRefPubMedPubMedCentral

Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2022;399(10321):234–6. https://doi.org/10.1016/S0140-6736(21)02844-0.CrossRefPubMed

10.

Hoffmann M, Kruger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447-456 e411. https://doi.org/10.1016/j.cell.2021.12.032.CrossRefPubMed

11.

Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature. 2022;602(7898):671–5. https://doi.org/10.1038/s41586-021-04389-z.CrossRefPubMed

12.

Rossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med. 2022;386(7):698–700. https://doi.org/10.1056/NEJMc2119236.CrossRefPubMed

13.

Schulz SR, Hoffmann M, Roth E, et al. Augmented neutralization of SARS-CoV-2 omicron variant by boost vaccination and monoclonal antibodies. Eur J Immunol. 2022;52(6):970–7. https://doi.org/10.1002/eji.202249841.CrossRefPubMedPubMedCentral

14.

Chang MC, Hwang JM, Jeon JH, et al. Fasting plasma glucose level independently predicts the mortality of patients with coronavirus disease 2019 infection: a multicenter retrospective cohort study. Endocrinol Metab (Seoul). 2020;35(3):595–601. https://doi.org/10.3803/EnM.2020.719.CrossRefPubMedPubMedCentral

15.

Long H, Li J, Li R, et al. Plasma glucose levels and diabetes are independent predictors for mortality in patients with COVID-19. Epidemiol Infect. 2022;150:e106. https://doi.org/10.1017/S095026882200022X.CrossRefPubMed

16.

Yang P, Wang N, Wang J, et al. Admission fasting plasma glucose is an independent risk factor for 28-day mortality in patients with COVID-19. J Med Virol. 2021;93(4):2168–76. https://doi.org/10.1002/jmv.26608.CrossRefPubMed

17.

Zhao Y, Xing H. Influence of fasting plasma glucose level on admission of COVID-19 patients: a retrospective study. J Diabetes Res. 2022. https://doi.org/10.1155/2022/7424748.CrossRefPubMedPubMedCentral

18.

Islam Z, Yamamoto S, Mizoue T, et al. Association of impaired fasting glucose and diabetes with SARS-CoV-2 spike antibody titers after the BNT162b2 vaccine among health care workers in a tertiary hospital in Japan. Vaccines (Basel). 2022. https://doi.org/10.3390/vaccines10050776.CrossRef

19.

Nimri R, Marianna R, Yackobovitch-Gavan M, et al. Symptoms and glycemic control in young people with type 1 diabetes following SARS-CoV-2 infection: an observational study. J Clin Endocrinol Metab. 2022. https://doi.org/10.1210/clinem/dgac288.CrossRefPubMed

20.

Vargas-Rodriguez JR, Valdes Aguayo JJ, Garza-Veloz I, et al. Sustained hyperglycemia and its relationship with the outcome of hospitalized patients with severe COVID-19 potential role of ACE2 upregulation. J Pers Med. 2022. https://doi.org/10.3390/jpm12050805.CrossRefPubMedPubMedCentral

21.

Tong L, Xiao X, Li M, et al. A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2. Nat Metab. 2022. https://doi.org/10.1038/s42255-022-00567-z.CrossRefPubMed

22.

China NHCotPsRo. Diagnosis and treatment plan for COVID-19(trial version 9). Int J Epidemiol Infect Dis. 2022. https://doi.org/10.3760/cma.j.cn331340-20220325-00065.CrossRef

23.

Chinese Diabetes S. National Office for Primary Diabetes C. National handbook for the prevention and control of diabetes in primary care. Zhonghua Nei Ke Za Zhi. 2019;58(10):713–35. https://doi.org/10.3760/cma.j.issn.0578-1426.2019.10.003.CrossRef

24.

Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature. 2022;604(7906):553–6. https://doi.org/10.1038/s41586-022-04594-4.CrossRefPubMedPubMedCentral

25.

Wang K, Jia Z, Bao L, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022;603(7903):919–25. https://doi.org/10.1038/s41586-022-04466-x.CrossRefPubMedPubMedCentral

26.

D’Addio F, Sabiu G, Usuelli V, et al. Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes. Diabetes. 2022. https://doi.org/10.2337/db22-0053.CrossRefPubMed

27.

Chen B, Lu C, Gu HQ, et al. Serum uric acid concentrations and risk of adverse outcomes in patients with COVID-19. Front Endocrinol (Lausanne). 2021. https://doi.org/10.3389/fendo.2021.633767.CrossRefPubMedCentral

28.

Hu F, Guo Y, Lin J, et al. Association of serum uric acid levels with COVID-19 severity. BMC Endocr Disord. 2021;21(1):97. https://doi.org/10.1186/s12902-021-00745-2.CrossRefPubMedPubMedCentral

29.

Zhang Y, Gao J, Huang K, et al. SARS-CoV-2 infection causes hyperglycemia in cats. J Infect Dis. 2022. https://doi.org/10.1093/infdis/jiac143.CrossRefPubMed

30.

Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. 2022;21(1):83. https://doi.org/10.1186/s12933-022-01512-w.CrossRefPubMedPubMedCentral

31.

Bjork J, Bonander C, Moghaddassi M, et al. COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants—surveillance results from southern Sweden, December 2021 to March 2022. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.18.2200322.CrossRefPubMedPubMedCentral

32.

Cheng SM, Mok CKP, Chan KC, et al. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.18.2200178.CrossRefPubMedPubMedCentral

Titel: SARS-CoV-2 omicron variant clearance delayed in breakthrough cases with elevated fasting blood glucose
verfasst von: Xiujun Zhang
Guocan Si
Huifen Lu
Wei Zhang
Shuqin Zheng
Zeyu Huang
Longgen Liu
Yuan Xue
Guojun Zheng
Publikationsdatum: 01.12.2022
Verlag: BioMed Central
Schlagwort: COVID-19
Erschienen in: Virology Journal / Ausgabe 1/2022
Elektronische ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-022-01877-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

SARS-CoV-2 omicron variant clearance delayed in breakthrough cases with elevated fasting blood glucose